Aneva Drug Delivery Systems

Aveva Drug Delivery Systems is a U.S.-based pharmaceutical drug-delivery and manufacturing business focused on transdermal patches and oral dissolvable film products. The company develops, manufactures, and supports proprietary and generic drug-device combination products, with particular strength in controlled-release transdermal systems. Aveva was acquired by DifGen Pharmaceuticals in April 2023 and now operates as a DifGen company with manufacturing sites in Miramar and Tamarac, Florida. Its known commercial and regulatory activities include transdermal products such as fentanyl, clonidine, nicotine, and an FDA-approved generic lidocaine 1.8% patch for post-herpetic neuralgia. The business appears to function primarily as a commercial-stage development and manufacturing platform rather than a discovery biotech with a broad novel therapeutic pipeline.